#	Pagina
attuale pagina	/open-h2020/projects/200627/index.html

Opendata, web and dolomites

ThruBlood

Clinical validation of Trop-2 as a serum biomarker for monitoring of disease-course in patients affected by breast and colon cancer

Total Cost €

EC-Contrib. €

Partnership

Views

Outcomes and
results

ThruBlood project word cloud

Explore the words cloud of the ThruBlood project. It provides you a very rough idea of what is the project "ThruBlood" about.

detection serum stage baseline drives 80 sensitivity tumour monitoring throughput strategy poor give 74 shown scientific disease biotech assay respect determinant colon therapeutic feasibility experimental care validation clinical procedure cancers biomarker cancer data represented recognize techniques biomarkers treatments accurate colorectal levels medicine invasive employed phase2 relapses possibility oncologist precision device transmembrane introduction types indications patented trop diagnosed scope breast proprietary population icona tool specificity survival bloodstream 100 business oncoxx samples circulating critical receptor standardized progression feasible validate course preliminary pursue thrublood patients collected metastases monitor demonstrating opportunity surveillance released

Project "ThruBlood" data sheet

The following table provides information about the project.

Coordinator	ONCOXX BIOTECH SRL Organization address address: VIA GARIBALDI VICO XVII 15 city: LANCIANO postcode: 66034 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Italy [IT]
Total cost	71˙429 €
EC max contribution	50˙000 € (70%)
Programme	1. H2020-EU.3.1.3. (Treating and managing disease)
Code Call	H2020-SMEINST-1-2015
Funding Scheme	SME-1
Starting year	2016
Duration (year-month-day)	from 2016-03-01 to 2016-08-31

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	ONCOXX BIOTECH SRL ONCOXX BIOTECH SRL Organization address address: VIA GARIBALDI VICO XVII 15 city: LANCIANO postcode: 66034 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	IT (LANCIANO)	coordinator	50˙000.00

Map

Project objective

A critical need in cancer care is the possibility to monitor tumour progression, through non-invasive techniques, to recognize relapses and/or metastases at a very early stage. The measurement of tumour biomarkers circulating into the bloodstream is a feasible way, as it can give indications also on patients’ response to therapeutic treatments, thus enabling the oncologist to pursue a precision-medicine strategy. In patients affected by breast and colon cancer, most serum biomarkers employed in the clinical practice have poor specificity and sensitivity to be used as monitoring tool of the cancer progression. Oncoxx Biotech has collected strong experimental data demonstrating that the transmembrane receptor Trop-2 drives progression of several tumour types. It has also been shown that Trop-2 is a determinant of breast cancer survival, and it is released in the bloodstream in patients with breast and colorectal cancer. In this respect, the results achieved in a preliminary clinical study have shown that all higher-than-baseline levels of circulating Trop-2 identify breast cancers with 100% specificity and 80% sensitivity and colon cancer with 100% of specificity and 74% of sensitivity. Therefore, scope of the ThruBlood project is to validate Trop-2 as a serum biomarker for monitoring disease-course in patients with breast and colon cancer. During Phase 1 we will: 1) assess the scientific feasibility of the proposed biomarker by extending the population of serum samples to analyse; 2) design the Clinical Validation Study to pursue in Phase2; 3) validate a standardized procedure for accurate measurement of the serum Trop-2 levels using a proprietary device (ICONA, patented by the applicant) with aim of providing high-throughput procedures for serum biomarker detection; 4) analyse and validate the business opportunity represented by the introduction of the ThruBlood assay in the current procedure adopted for surveillance of cancer diagnosed and treated patients.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "THRUBLOOD" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "THRUBLOOD" are provided by the European Opendata Portal: CORDIS opendata.